Exelixis has re-established revenue momentum, with 2026Q3 revenue rising 10.2% year over year to $658.7M after a mid-2025 dip, while gross margin held near-saturated levels between 95.6% and 97.2% and operating margin expanded from 25.2% to 40.8% over the observed window.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue recovered to $658.7M in 2026Q3 (up 10.2% year over year) with operating margin expanding from 25.2% in 2024Q3 to 40.8%, suggesting operating income is scaling well ahead of revenue against a stable overhead base.
Multiple bullish theses on Exelixis, Inc. have been highlighted by Business Invest's Substack and Investing With Purpose, indicating strong analyst confidence in the stock.
EXEL's trailing and forward P/E ratios of 18.52 and 15.24 (as of January 13th) suggest attractive valuation relative to earnings potential.
The stock was trading at $44.08 as of January 13th, showing potential upward momentum from previous levels of $37.42.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.94+6.0% vs $0.89 | $659M+1.9% vs $647M |
Q3 2026 Aug 5, 2026 | $0.91+6.7% vs $0.85 | $629M-1.2% vs $636M |
Q2 2026 May 5, 2026 | $0.87+13.7% vs $0.77 | $611M+0.5% vs $608M |
Q1 2026 Feb 10, 2026 | $0.94+22.1% vs $0.77 | $599M+0.4% vs $597M |
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Exelixis NASDAQ: EXEL reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal cancer.
Benchmark EXEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Exelixis, Inc. (EXEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $69.57 | $17.49B | 20.10 | 6.98% | 35.45% | 45.54% | — | |
| $119.65 | $24.25B | 60.28 | 21.22% | 6.71% | 7.11% | — | |
| $45.90 | $7.7B | -9999.00 | -5.25% | -0.02% | -0.02% | — | |
| $234.76 | $14.75B | 73.75 | 4.88% | 4.37% | 4.62% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — |
Exelixis, Inc. (EXEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Exelixis, Inc. (EXEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Aug 5, 2026·SEC
May 29, 2026·SEC
Get notified when EXEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Exelixis, Inc. (EXEL) stock FAQ — growth, dividends, profitability & financials explained
Exelixis, Inc. (EXEL) reported $2.50B in revenue over the trailing twelve months. Revenue was $2.32B in fiscal year 2025. That is 21996% more than the $10.5M of fiscal year 1999.
Exelixis, Inc. (EXEL) grew revenue by 9.1% over the trailing twelve months, compared with the twelve months before.
Yes. Exelixis, Inc. (EXEL) earned $885.1M in net income over the trailing twelve months (a 35.5% net margin).
Exelixis, Inc. (EXEL) had a return on equity (ROE) of 45.5% over the trailing twelve months. That is well above the market's typical 10-15%.
Exelixis, Inc. (EXEL) generated $1.15B in free cash flow over the trailing twelve months.
